Patient Death Obscures Efficacy Success For Sophiris’ Intratumoral Prostate Cancer Therapy
Executive Summary
The bad outweighed the good for Sophiris on a day in which it unveiled promising Phase IIb data for topsalysin, but also took a huge stock hit with news of a patient death in the trial.